Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT02590042
Other study ID # SJS-CT-001
Secondary ID
Status Not yet recruiting
Phase Phase 1
First received October 21, 2015
Last updated July 17, 2017
Start date October 2017
Est. completion date January 2021

Study information

Verified date July 2017
Source AdiSave Inc.
Contact Keren Leibson, PhD
Phone 416 785-7536
Email info@adisave.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A single-arm, open-labeled, single-center, descriptive and exploratory safety trial using ADSC-SVF-002. ADSC-SVF-002 is an autologous adipose derived stem cell (ADSC)-containing stromal vascular fraction (SVF) obtained from subcutaneous fat harvested by liposuction from a patient. As a cellular therapy product, ADSC-SVF-002 (fresh or cryopreserved) will be administered subcutaneously via injection, with or without unprocessed autologous fat (fresh or cryopreserved), into soft tissue defects and abnormally healing wounds. The primary objective of the trial is to demonstrate the safety of ADSC-SVF-002 in a population of subjects with soft tissue defects or abnormal wound healing who are still symptomatic despite being managed by conventional therapies.


Description:

Protocol Number: SJS-CT-001 Phase: Pilot study Methodology: Open label, single-arm Study Duration: Six months after accrual and treatment of the last patient Study Center(s): Single-center Objectives: To demonstrate the safety of subcutaneous administration of autologous ADSC-SVF-002 in a population of subjects with soft tissue defects or abnormal wound healing who are still symptomatic despite being managed by conventional therapies.

Number of Subjects: 10 Diagnosis and Main Inclusion Criteria: Subject has soft tissue deficiencies, soft tissue post traumatic malformations, scars, and/or abnormal wound healing.

Study Product, Dose, Route, Regimen: ADSC-SVF-002. 1.0x106 cells/mL defect (when administered without fat) to 1.2x106 cells/mL defect (when administered with fat). Subcutaneous injection.

Duration of administration: Administration of the product takes approximately 30 minutes. Administered once.

Reference therapy: N/A

Statistical Methodology: Safety outcomes will be reported with descriptive statistics. Secondary (efficacy) outcomes will be assessed relative to baseline (screening) as follows:

- For outcomes assessed at multiple follow-up visits, one-way ANOVAs followed by the Tukey's test will be conducted

- For outcomes assessed at one follow-up visit, a Student's t-test will be conducted.

Data will be reported as mean ± SD and p<0.05 will be considered significant.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 10
Est. completion date January 2021
Est. primary completion date October 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

1. Subject has soft tissue deficiencies, soft tissue post traumatic malformations, scars, and/or abnormal wound healing.

2. Subject is an adult male or non-pregnant female between the ages of 18 to 80 years.

3. Subject is able to undergo a liposuction procedure in the opinion of the investigator or per facility guidelines.

4. Subject is able to read, understand and sign a written Informed Consent to participate in the study.

5. Subject is willing and able to comply with the study protocol, including requirements for taking and abstaining from medications.

Exclusion Criteria:

1. The subject is a woman of child-bearing potential (not surgically sterile or post-menopausal for at least 1 year as documented in medical history), but is not using a highly effective method of contraception [oral, injected or implanted hormonal methods of contraception; intrauterine device (IUD) or intrauterine system (IUS); condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository; or male sterilization (vasectomy)].

2. Subject has a history of cancer and/or any known conditions/diseases prone to malignancy.

3. Subject has significant cardiac, renal, or hepatic failure or any other disease that may interfere with the ability to interpret the results of the study.

4. Subject has an infection, cellulitis, or osteomyelitis diagnosed by MRI and microbiologic culture results.

5. Subject has an autoimmune disorder.

6. Subject has a connective, metabolic or atrophic skin disease.

7. Subject is under chronic anticoagulant therapy.

8. Subject has a Body Mass Index (BMI) >30.

9. Subject is positive for HBs antigen, HCV antibody, or HIV antibody.

10. Subject has received other investigational drug/drugs or unapproved medication within 3 months before registration in this study.

11. Subject has a history of hematopoietic stem cell transplantation or radio immunotherapy.

12. Subject has a recent and significant weight loss, the cause of which has not been determined.

13. Subject has a history of hereditary linked malignancy in a first-degree relative (parent, child, sibling).

14. Subject is participating in another clinical trial within 6 weeks prior to registration in this study.

15. Subject has a psychiatric disorder that in the judgment of the investigator could interfere with provision of informed consent, completion of tests, therapy, or follow-up.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
ADSC-SVF-002
ADSC-SVF with the following identity: Less than or equal to 10% each CD34 and CD45 positive cells At least 70% each CD90, CD73 and CD105 positive cells Viability of at least 85% Mean Florescence Intensity of less than or equal to 100 C12FDG 0-5-2.5x10^6 cells/g of liposuctioned (hydrated fat)

Locations

Country Name City State
Canada Forest Hill Institute of Aesthetic Plastic Surgery Toronto Ontario

Sponsors (1)

Lead Sponsor Collaborator
AdiSave Inc.

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Continuous monitoring of safety via laboratory tests and physical examinations Continuous monitoring of safety as requested by Health Canada Screening, 48 hours after procedure, and at post-treatment months 1, 2 and 6
Secondary Physician satisfaction with wound cosmesis, assessed using the Hollander Wound Evaluation Scale Screening, 48 hours after procedure, and at post-treatment day 10 and months 1-6
Secondary Patient satisfaction with wound cosmesis, assessed using the 100 mm vertical line visual analogue scale Screening, 48 hours after procedure, and at post-treatment day 10 and months 1-6
See also
  Status Clinical Trial Phase
Completed NCT04806594 - Clinical Investigation on the Safety and Clinical Performance of Papix Acne Scar. N/A
Completed NCT01700595 - Preexpanded Perforator Flaps in Children N/A
Recruiting NCT03782038 - Study to Evaluate the Efficacy of a Micro Coring Device for the Treatment of Scars of the Cytrellis Micro-Coring Device for the Treatment of Scars N/A
Recruiting NCT06202274 - Clinical Study to Evaluate the Safety and Efficacy of Candela Technology N/A
Completed NCT01932359 - Rapidly Absorbable Versus Non-absorbable Sutures for Mohs Surgery Repair on the Face: a Randomized Controlled Split-scar Study N/A
Completed NCT01091181 - The Effect of Hysterotomy Technique on the Rate of Large Defects in the Hysterotomy Scar N/A
Unknown status NCT00969475 - The Effects of Fractional Carbon Dioxide (CO2) Laser Treatment Prior to Wound Closure N/A
Recruiting NCT06021275 - Microneedling With Regular Insulin Versus Microneedling Alone in Treatment of Atrophic Scars N/A
Recruiting NCT02195063 - Survey Study for Pain Management, Wound Care, Scar Care or UDT Phase 4
Terminated NCT00803140 - Cutaneous Scarring of Scalpel Versus Cautery N/A
Not yet recruiting NCT04593706 - Comparison of the Efficacy of Different Steroids in the Treatment of Abnormal Scars (Keloids, Hypertrophic Scars) N/A
Recruiting NCT05847530 - Pilot Evaluation of the Cynosure Potenza™ System for Treatment of Cosmetic Dermatologic Skin Conditions N/A
Withdrawn NCT01350739 - The Umbilical Access in Laparoscopic Surgery N/A
Completed NCT02145130 - Phase I Study for Autologous Dermal Substitutes and Dermo-epidermal Skin Substitutes for Treatment of Skin Defects Phase 1
Completed NCT01358838 - Ablative 10600 nm Fractional Laser Therapy for the Treatment of Scars N/A
Completed NCT03880058 - Safety and Efficacy of SLI-F06 in Wound Healing and Scar Appearance Phase 1/Phase 2
Recruiting NCT05528328 - Post-surgical Scars After the Use of CACIPLIQ20 Phase 3
Completed NCT00450775 - Evaluation of the Efficacy, Tolerability, and Patient Acceptance of Dermatix Q for the Prevention and Management of Scars Phase 4
Completed NCT00580736 - Optical Clearing of the Skin in Conjunction With Laser Treatments Phase 1
Withdrawn NCT04269317 - Clinical Study to Evaluate the Safety and Effectiveness of the Treatment With Tixel C on Acne Scars N/A

External Links